Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

• Main Authors: Nicolino Ruperto (Author), Hermine I. Brunner (Author), Zbigniew Zuber (Author), Nikolay Tzaribachev (Author), Daniel J. Kingsbury (Author), Ivan Foeldvari (Author), Gerd Horneff (Author), Elzbieta Smolewska (Author), Richard K. Vehe (Author), Anasuya Hazra (Author), Rong Wang (Author), Charles A. Mebus (Author), Christine Alvey (Author), Manisha Lamba (Author), Sriram Krishnaswami (Author), Thomas C. Stock (Author), Min Wang (Author), Ricardo Suehiro (Author), Alberto Martini (Author), Daniel J. Lovell (Author), for the Pediatric Rheumatology International Trials Organization (PRINTO) (Author), the Pediatric Rheumatology Collaborative Study Group (PRCSG) (Author)
• Format: Book
• Published: BMC, 2017-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was to characterize the PK, safety, and taste acceptability of tofacitinib in patients with JIA. Methods This Phase 1, open-...